ArticleJournal of the National Cancer Institute2014

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.

Zhiyong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.